New drug cocktail aims to reverse fatty liver damage in diabetics
NCT ID NCT07303803
First seen Jan 07, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This study tests whether a drug called chiglitazar, combined with anti-inflammatory and liver-protecting therapies, can improve liver health in people who have both MASH (a severe fatty liver disease) and type 2 diabetes. About 300 adults will receive either the drug combo or a placebo for several months. The main goal is to see if the treatment can resolve liver inflammation without worsening scarring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ditan Hospital of integrated traditional Chinese and Western Medicine Center
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100015, China
-
Renji hospital of Shanghai Jiao Tong University School of Medical
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200001, China
-
Ruijin Hospital of Shanghai Jiaotong University School of Medicine
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200020, China
-
Shanghai Public Health Clinical Center
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200083, China
-
Shanghai Punan Hospital of Pudong New District (Punan Branch of Renji Hospital, Shanghai Jiaotong University School of Medicine)
RECRUITINGShanghai, Shanghai Municipality, 200125, China
-
Southern Hospital
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510515, China
-
Southwest Hospital of Third Military Medical University
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, 400038, China
-
Taihe Hospital
NOT_YET_RECRUITINGShiyan, Hubei, 442000, China
-
The First Affiliated Hospital of Fujian Medical University
NOT_YET_RECRUITINGFuzhou, Fujian, 350005, China
-
The First Affiliated Hospital of Jilin University
NOT_YET_RECRUITINGChangchun, Jilin, 130021, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
NOT_YET_RECRUITINGXi’an, Shanxi, 710061, China
-
The First Affiliated Hospital of Zhejiang University
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310003, China
-
The First Teaching Hospital of Xinjiang Medical University
NOT_YET_RECRUITINGÜrümqi, Xinjiang, 830054, China
-
The Third Affiliated Hospital of Sun Yat-sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510000, China
-
Tianjin Second People's Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300192, China
-
Wuhan Union Hospital of Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, Hebei, 430022, China
-
Xiangya hospital of Central South University
NOT_YET_RECRUITINGChangsha, Hunan, 410008, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Chiglitazar (a drug that targets metabolism and inflammation), vitamin E, and polyene phosphatidylcholine
What this could lead to
If successful, this combination could offer a new treatment option for people with both MASH and type 2 diabetes, potentially reducing liver inflammation and scarring.
What could go wrong
This is an early Phase 2 trial with only 300 participants, so results may not apply to everyone. The treatment involves multiple drugs, which could increase side effects or interactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.